Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5883056 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 8 Pages |
Abstract
The present report focuses on management strategies for the myeloproliferative neoplasm according to the structure and processes we use within our center, a large tertiary unit in central London. The standard procedures for achieving an accurate diagnosis and risk stratification and therapeutic strategies for these diseases with a detailed focus on contentious areas are discussed. In the 9 years after the description of the Janus kinase 2 mutation, this field has altered quite radically in several aspects. For example, a new therapeutic paradigm exists, especially for myelofibrosis. We share how our unit has adapted to these changes.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Claire N. Harrison, Donal P. McLornan, Yvonne A. Francis, Claire Woodley, Lizzie Provis, Deepti H. Radia,